AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02266277 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Arm 5: IVR call
Description: Non electronic patient portal users will be randomized to receive an IVR call with educational information about influenza vaccines, notification of local flu clinic schedules and elicit patient response to vaccination status and barriers.
Study NCT03159507 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MAG-EPA
Description: Based on the result of the participant's Omega-3 index obtained from the blood sampling of visit 1, the daily dose of MAG-EPA will be adjusted to obtain an Omega-3 Index of 8.
Study NCT03900923 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 98% pure CBD
Description: A Bayesian optimal interval (BOIN) design was used, such that participants were assigned to cohorts of size 3 receiving doses of 3, 6, or 9 mg/kg/day, depending on the treatment response of participants in prior cohorts. The BOIN design has ended, and two doses have been tested and eliminated (3 and 6 mg/kg/day). We are now examining 9 mg/kg/day exclusively.
Study NCT03524287 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotic Assisted No.10 Lymph Node Dissections
Description: After exclusion of T4b, bulky lymph nodes, or distant metastasis case et al. Robotic assisted spleen-preserving No.10 lymph node dissections will be performed with curative treated intent in patients with locally advanced upper third gastric adenocarcinoma
Study NCT00260065 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: 20mg/m\^2, IV on days 1-5 of each 28 day cycle; until progression, death or unacceptable toxicity develops.
Study NCT03564821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivosidenib
Description: Ivosidenib is an inhibitor of the protein IDH1
Study NCT03610503 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music
Description: Participants in this arm will listen to music during the EMG testing
Study NCT04291794 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: 2mg/kg single bolus
Study NCT02465541 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT02465541 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: questionnaire administration
Description: Ancillary studies
Study NCT00952471 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Evidence Based Intervention to order set
Description: The order set was altered to include evidence based care items
Study NCT02840552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-Fluoromethylcholine (18F-FCH)
Description: FCH PET/CT
Study NCT02532829 — intervention group
Intervention type: OTHER
Intervention: blood sample analysis
Description: Measurement of GLP-1, Peptide YY, Glucose and Insulin before and 30-60-120 minutes after Oral Mixed Meal Tolerance Test.
Study NCT01039610 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linezolid
Description: 600 mg BID, 14 Days
Study NCT01039610 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: 40 mg single dose
Study NCT02393976 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: IMMUNONUTRITION
Description: IMMUNONUTRITION SUPLEMENTS PERIOPERATIVE
Study NCT02393976 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: STANDART NUTRITION
Description: STANDART NUTRITION PERIOPERATIVE
Study NCT01475331 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Following lavage with either 80% ethanol (control group) or normal saline (study group), cysts will be injected with a cocktail of 3mg/ml paclitaxel and 19mg/ml gemcitabine.
Study NCT04540757 — intervention group
Intervention type: PROCEDURE
Intervention: Surgery
Description: Participants will be randomised to receive surgery as part of multi-modality treatment
Study NCT02430298 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: Drug: Melatonin 20 mg/ 10 ml melatonin suspension gargle for 2 minutes before radiation 15 minutes and 20 mg melatonin gelatin capsule taken orally after 21:00 hours each night throughout the study
Study NCT02430298 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matched Placebo
Description: Drug: Melatonin 20 mg/ 10 ml placebo suspension gargle for 2 minutes before radiation 15 minutes and 20 mg placebo gelatin capsule taken orally after 21:00 hours each night throughout the study
Study NCT01402206 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Structured patient-centered follow up of depression
Description: All patients who agree to participate in the study are diagnosed by their GP with a diagnostic assessment instrument called PRIME-MD. Participants in the intervention group visit their GPs at baseline and 4, 8, and 12 weeks. At each visit, participants complete MADRS-s for the assessment of depression severity and discuss the results with their GP in a patient-centered consultation. We have chosen to use the MADRS/MADRS-S depression rating scale in this study because it is a easy to use standard instrument especially suitable for measuring change in depressive symptoms.~The control group receives treatment as usual (no intervention).
Study NCT04540757 — intervention group
Intervention type: PROCEDURE
Intervention: No surgery
Description: Participants will be randomised to receive no surgery as part of multi-modality treatment
Study NCT04291794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol Injection [Diprivan]
Description: Tritiated Target-Controlled Infusion
Study NCT01404013 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ICS/LABA
Description: Budesonide 160µg and Formoterol 4.5µg, 1puff ,twice a day, for 8 weeks
Study NCT01404013 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast
Description: Montelukast 10mg ,every night, for 8 weeks
Study NCT01404013 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ICS/LABA and Montelukast
Description: Budesonide 160µg and Formoterol 4.5µg, 1puff, twice a day, for 8 weeks; Montelukast 10mg ,take orally ,every night for 8 weeks
Study NCT03411109 — intervention group
Intervention type: DRUG
Intervention: Hydromorphone Hydrochloride
Description: All intrathecal injections were performed preoperatively using a 22g or 25 g Whitacre or 24g Sprotte spinal needle. The IA regimen, medication(s) and dose(s), was at the discretion of the attending anesthesiologist, and consisted of one of the following regimens: (1) hydromorphone + local anesthetic (IA-L), or (2) hydromorphone only (IA-O). In patients receiving IA, no other interventional locoregional analgesic techniques (such as rectus sheath blocks or transversus abdominis plane blocks) were utilized.
Study NCT01731730 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Injection
Description: 3mL solution for intrathecal injection; Vehicle formulation designed to mimic AYX1 Injection (with no active drug)
Study NCT01731730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AYX1 Injection 110 mg
Description: 3mL solution for intrathecal injection with 110 mg of AYX1
Study NCT01731730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AYX1 Injection 330 mg
Description: 3mL solution for intrathecal injection with 330 mg of AYX1
Study NCT03208920 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pro-Omega
Description: Pro-Omega (Nordic Naturals, Watsonville, CA, USA). Each Pro-Omega capsule is 550 mg. Must take 4400 mg/day x 6 months.
Study NCT03208920 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: ProOmega Placebo
Description: Placebo Comparator: soybean (Nordic Naturals, Watsonville, CA, USA). Each soybean capsule is 550 mg. Must take 4400 mg/day x 6 months.
Study NCT02170363 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Left Ventricular Assist System (LVAS)
Description: Implantation of left ventricular assist device for hemodynamic support
Study NCT01394614 — intervention group
Intervention type: BIOLOGICAL
Intervention: A/H1N1 vaccine
Description: Verify if exposure to Arepanrix vaccine increase risk of developing narcolepsy in 16 weeks post-vaccination.
Study NCT03987932 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NEAT!2
Description: Participants randomized to NEAT!2 will have their NEAT!2 app turned on after randomization. When 30 minutes of continuous non-movement or sedentary time is detected, the NEAT!2 app will provide a vibration or audio notification as well as display a reminder on the phone's lock/home screen. Participants will be asked to use the app for the 3 months of the intervention. Participants will be given an initial goal to reduce total sedentary time by 30 minutes/day, ultimately progressing to a 90 minute/day reduction by 3 months. After the 3-month assessment, participants randomized to NEAT!2 will have the option to continue using the app until 6 months.
Study NCT03987932 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: NEAT!2+Calls
Description: Participants in this group will have their NEAT!2 app turned on after randomization. In addition, to receiving the identical app and given the same goals as participants randomized to NEAT!2, NEAT!2+Calls participants will receive 10-15 minute bi-weekly coaching calls. After the 3-month assessment, participants will have the option to continue using the app until 6 months. During this time, participants will not receive any coaching calls.
Study NCT00048932 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Double-blind Abatacept
Description: Concentrate and diluted in a solution, IV, 500 mg (body weight \< 60 Kg); 750 mg (body weight 60-100 Kg); 1000 mg (body weight > 100 Kg), Once daily, Day 1, 15, and 29.
Study NCT03987932 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Delayed NEAT!2
Description: Participants randomized to Delayed NEAT!2 will not receive any contact or app between baseline and 3 months. However, after completing the 3-month assessment, participants will receive the NEAT!2 application. Participants will then have the option to use the app between 3 and 6 months.
Study NCT00917072 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Didactic
Description: Group #1: will have a focused, interactive power point lecture on the background, content and guidelines for a good handoff (focus on a standardized electronic hand-off tool). They will have an exercise to complete
Study NCT00779233 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zidovudine tablets 300 mg
Study NCT00048932 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Double-blind Placebo
Description: Concentrate and diluted in a solution, IV, 0 mg, Once daily, Day 1, 15, and 29.
Study NCT00779233 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zidovudine tablets 300 mg
Study NCT05830331 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ERASS Pathway
Description: Enhanced Recovery After Spinal Surgery
Study NCT00682292 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thymoglobulin (ATG)
Description: Thymoglobulin: 1.25 mg/kg per day from day 0 to day 7 post transplantation
Study NCT00682292 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daclizumab
Description: Daclizumab: 1mg/kg at day 0, 14, 28, 42 and 56 post transplantation
Study NCT00050440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trabectedin
Description: Trabectedin 1.3 mg/m2 administered intravenously every 21 days.
Study NCT00050440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 4 mg administered orally (by mouth) the day before the trabectedin dose, 30 minutes before the trabectedin dose, and for 2 days following the trabectedin dose
Study NCT00684073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: buprenorphine
Description: 2 mg buprenorphine and 8 mg buprenorphine tablets at doses from 2 to 16 mg buprenorphine daily for first two days of study
Study NCT00684073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: buprenorphine/naloxone
Description: 2/0.5 mg buprenorphine/naloxone and 8/2 mg buprenorphine/naloxone tablets at doses from 2/0.5 mg buprenorphine/naloxone to 16/4 mg buprenorphine/naloxone daily for last 3 days of study
Study NCT02619461 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise at 70%VO2max on a recumbent bicycle for 30 minutes to investigate the effects of exercise at high intensities on appetite and biomarkers of appetite and inflammation.
Study NCT00490477 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Polymyxin -B fiber hemoperfusion system
Description: two hours treatment for two days
Study NCT00072098 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: adenovirus vector
Study NCT00072098 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: interleukin-12 gene
Study NCT03539900 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupropion Hydrochloride, Naltrexone Hydrochoride Drug Combination
Description: NB medication will combine BUPROPION HYDROCHLORIDE (360 mg/day) and NALTREXONE HYDROCHLORIDE (32 mg/day). Taken daily in pill form.
Study NCT03539900 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be inactive and taken daily in pill form.
Study NCT02890940 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pet Therapy
Description: Patients will be asked to complete the standardized QLQ-C30/BN20 questionnaires. Following completion of the questionnaires, a trained pet therapy dog will be brought to the patients for approximately 10 minutes. After approximately 10 minutes, the dog will be removed and the patients will be asked to re-complete the standardized QLQ-C30/BN20 questionnaires. Patients will be photographed and videographed during this time.~Finally, patients will be asked to talk about how their perspectives on life have changed with their diagnosis. These responses will be captured for use in the art exhibit created from images collected during the study.
Study NCT03652090 — intervention group
Intervention type: PROCEDURE
Intervention: cell sampling
Description: nasal brushing to collect cells
Study NCT00917072 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Didactic+Simulation
Description: Group #2: will undergo the same power point lecture ( as in Group #1) with an additional intervention focused not only on the hand-off tool, but on a standardized hand-off process using an OSCE exercise (objective structured clinical exam). This group will be trained about the effective implementation of the hand-off tool. They will be taught how to standardize the hand-off process and will be given an opportunity to practice with their peers in the HFH simulation center
Study NCT00917072 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: The control group received no formal handoff training other than an introduction to handoffs for all interns during orientation at the start of the academic year along with expected ward based experiential training from senior residents throughout the intern year.
Study NCT03205852 — intervention group
Intervention type: OTHER
Intervention: questionnaire
Description: fulfillment of questionnaire
Study NCT00904436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipratropium (Atrovent)
Description: Bronchodilator Treatment: Subjects will inhale 1 unit dose vial of aerosolized ipratropium (500 mcg of ipratropium (Atrovent) mixed in 2.5 ml of saline).
Study NCT00111176 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Endovascular repair
Description: Endovascular repair.
Study NCT00111176 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Surgical
Description: Surgical endovascular repair
Study NCT04619446 — intervention group
Intervention type: DEVICE
Intervention: Removable Twin Block
Description: Twin block appliance (RFA) was introduced by William Clark in 1988. Many modifications for this appliance have been introduced lately. It has been named twin block for the characteristic of two unattached maxillary and mandibular plates with acrylic bite blocks, which makes 70o angle when come in contact with each other. Delta clasps are added for better retention of the appliance. This appliance plays a vital role in the treatment of mandibular retrognathia
Study NCT04619446 — intervention group
Intervention type: DEVICE
Intervention: Fixed Functional , AdvanSync Appliance
Description: AdvanSync2 (Ormco Co., Glendora, Calif) is a FFA being introduced recently as an advancement of Herbst appliance. It is a molar-to-molar appliance, connected by a telescopic rod, which allow for simultaneous treatment with braces. It is much smaller in size than the conventional Herbst appliance and reduces treatment duration up to six to nine months. It is much more acceptable by the patients as they complain less about sores and discomfort, and is esthetically pleasant since it's not visible in the mouth. Short arms of this appliance help to decrease irritation and discomfort of the patient, and helps to advance the mandible in a constant forward direction to encourage growth, and reduce malocclusion.
Study NCT00459680 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser acupoint treatment
Description: Laser
Study NCT00459680 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Needle acupuncture on ST36 and LI11.
Study NCT01250236 — intervention group
Intervention type: DRUG
Intervention: brimonidine 0.1%
Description: brimonidine 0.1% eye drops twice daily
Study NCT01250236 — intervention group
Intervention type: DRUG
Intervention: placebo
Description: sodium hyaluronate 1.8mg/ml eye drops twice daily
Study NCT01864629 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Focused contraception counseling
Description: This intervention will be provided to those randomized to the intervention group only. This counseling will follow a pre-written, structured script describing all contraceptive methods in rank order starting with most effective to least effective in preventing unplanned pregnancy.
Study NCT00564135 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: on Foley time
Description: A-no Foley B-remove Foley at 7AM in the morning of postoperative day 1 C-remove Foley at 7AM in the morning of postoperative day 2
Study NCT03512028 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RLIC
Description: See descriptions under arm/group descriptions. RLIC is delivered for 8 visits. Visits 1-3 occur on consecutive work days and visits 4-8 occur on alternating week days.
Study NCT03512028 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham conditioning
Description: See descriptions under arm/group descriptions. Sham conditioning is delivered for 8 visits. Visits 1-3 occur on consecutive work days and visits 4-8 occur on alternating week days.
Study NCT03512028 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Muscle strength training
Description: All participants undergo muscle strength training of the wrist extensor muscles on one side. Strength training follows standard American College of Sports Medicine guidelines for frequency, intensity, progression etc. Strength training is provided at visits 3-8
Study NCT03512028 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Muscle strength training
Description: All participants undergo muscle strength training of the wrist extensor muscles on one side. Strength training follows standard American College of Sports Medicine guidelines for frequency, intensity, progression etc. Strength training is provided at visits 3-8
Study NCT03512028 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Driving training
Description: All participants undergo training of a complex cognitive-motor task using a driving simulator. Participants learn to 'drive' on a virtual course, maximizing speed and minimizing errors. Participants perform the driving task once each day for visits 3-8.
Study NCT03512028 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Driving training
Description: All participants undergo training of a complex cognitive-motor task using a driving simulator. Participants learn to 'drive' on a virtual course, maximizing speed and minimizing errors. Participants perform the driving task once each day for visits 3-8.
Study NCT03512028 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Balance training
Description: All participants undergo training on a balance board, learning to hold the board level with equal weight on each leg. Participants perform the balance task for 15, 30-second trials per day at visits 3-8.
Study NCT03512028 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Balance training
Description: All participants undergo training on a balance board, learning to hold the board level with equal weight on each leg. Participants perform the balance task for 15, 30-second trials per day at visits 3-8.
Study NCT04026633 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CAA
Description: Participants will write about the use of PBS and alcohol use.
Study NCT04026633 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Participants will write about eating and exercise.
Study NCT00048932 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Open-label Abatacept
Description: Concentrate and diluted in a solution, IV, 500 mg (body weight \< 60 Kg); 750 mg (body weight 60-100 Kg); 1000 mg (body weight > 100 Kg), Once daily, Every 28 days.
Study NCT03470597 — intervention group
Intervention type: OTHER
Intervention: dietary iodine restriction on subjects with iodine overload
Description: In this case registry study (observational study),all intervention will be performed not for research purposes, but only part of routine treatment, which will be recorded in database of the registry study.